Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
McEvoy SH, Halpenny DF, Viteri-Jusué A, Hayes SA, Plodkowski AJ, Riely GJ, Ginsberg MS. McEvoy SH, et al. Among authors: hayes sa. Lung Cancer. 2017 Jun;108:62-65. doi: 10.1016/j.lungcan.2017.02.024. Epub 2017 Mar 1. Lung Cancer. 2017. PMID: 28625649 Free PMC article.
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, Tobi Y, Heller G, Ahn L, Hayes SA, Young RJ, Arcila ME, Berger M, Chaft JE, Ladanyi M, Riely GJ, Kris MG. Yu HA, et al. Among authors: hayes sa. JAMA Oncol. 2020 Jul 1;6(7):1048-1054. doi: 10.1001/jamaoncol.2020.1260. JAMA Oncol. 2020. PMID: 32463456 Free PMC article. Clinical Trial.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
Choudhury NJ, Makhnin A, Tobi YY, Daly RM, Preeshagul IR, Iqbal AN, Ahn LS, Hayes SA, Heller G, Kris MG, Riely GJ, Yu HA. Choudhury NJ, et al. Among authors: hayes sa. JCO Precis Oncol. 2021 Apr 22;5:PO.21.00005. doi: 10.1200/PO.21.00005. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250398 Free PMC article. Clinical Trial.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Elkrief A, Makhnin A, Moses KA, Ahn LS, Preeshagul IR, Iqbal AN, Hayes SA, Plodkowski AJ, Paik PK, Ladanyi M, Kris MG, Riely GJ, Michor F, Yu HA. Elkrief A, et al. Among authors: hayes sa. Clin Cancer Res. 2023 Apr 14;29(8):1423-1428. doi: 10.1158/1078-0432.CCR-22-3484. Clin Cancer Res. 2023. PMID: 36729110 Free PMC article.
104 results